<DOC>
	<DOCNO>NCT00875368</DOCNO>
	<brief_summary>Rationale : Improving cellular immunity mean increase CD4 cell one goal antiretroviral therapy HIV , achieve mean virological suppression . A certain group patient , call `` immunologic non responder '' , fail reach acceptable CD4 cell increase despite adequate virologic response antiretroviral treatment . Recently new antiretroviral agent , maraviroc ( CelsentryÂ® ) , register treatment patient infect CCR5 tropic HIV-1 virus . However , data available suggest treatment maraviroc lead immune recovery ( increase CD4 cell ) patient infect dual/mixed tropic HIV-1 virus , absence virologic response . This suggest alternative mechanism immune recovery , could especially beneficial group patient . Hypothesis : Maraviroc , yet unknown mechanism , stimulate immune recovery increase CD4+ cell count . Objective : The primary objective confirm hypothesis maraviroc stimulate immune recovery ; secondary objective explore , virologic immunologic investigation , underlie mechanisms hypothesis . Study design : multicentre , randomize , placebo-controlled , double blind , exploratory mechanistic study . Study population : HIV-1 infected patient 18 year old , meet inclusion criterion . Intervention : One group receive maraviroc ( dose dependent co-medication ) , group placebo . Main study parameters/endpoints : A 30 % increase CD4 cell rise treatment group ( compare placebo ) . Nature extent burden risk associate participation , benefit group relatedness : 1 . In treatment group subject start registered antiretroviral agent ( maraviroc ) . 2 . During treatment year patient perform several study visit , probably three compare regular visit outpatient clinic . 3 . Each visit , blood drawn venepuncture immunologic virologic investigation ( see flow chart ) .</brief_summary>
	<brief_title>Maraviroc Immune Recovery Study</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Age 18 year old HAART maximal treatment interruption two week viral suppression ( &lt; 50 copies/ml ) 6 month And either : CD4+ count &lt; 200 cells/microliter minimal one year treatment HAART ( study group one ) OR CD4+ cell count 200 350 cells/microliter minimal two year treatment HAART ( study group two ) HAART consist combination tenofovir didanosine Active infection antimicrobial treatment Acute hepatitis B C Chronic hepatitis B C treatment ( peg ) interferon and/or ribavirin ( Note : patient untreated chronic hepatitis B C include ) Immunosuppressive medication Radiotherapy chemotherapy past 2 year Pregnancy breastfeed infant Subjects know hypersensitivity maraviroc peanut , excipients dye follow : Excipients tablet : microcrystalline cellulose , dibasic calcium phosphate ( anhydrous ) , sodium starch glycolate , magnesium stearate . Filmcoat : [ Opadry II Blue ( 85G20583 ) contains FD &amp; C blue # 2 aluminium lake , soya lecithin , polyethylene glycol ( macrogol 3350 ) , polyvinyl alcohol , talc titanium dioxide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HAART</keyword>
	<keyword>CD4 cell</keyword>
	<keyword>Immunologic non-responders</keyword>
	<keyword>Immunology</keyword>
	<keyword>treatment experience</keyword>
</DOC>